9 Jul 2010	European Biopharmaceutical Enterprises Appoints Søren Tulstrup, President & CEO of Santaris Pharma A/S, to its Board of Directors
23 Jun 2010	Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-targeted Medicines for the Treatment of Cardiovascular Disease
4 Jun 2010	Santaris Pharma A/S Receives Red Herring Top 100 Europe Award
26 Apr 2010	Santaris Pharma A/S advances RNA-targeted drug development candidate against PCSK9, an important new target for the treatment of high cholesterol
4 Dec 2009	New data show breakthrough microRNA-targeted therapy developed using Santaris Pharma A/S proprietary LNA technology holds promise as new treatment for Hepatitis C
28 Oct 2009	Santaris Pharma A/S expands executive team, appoints Chief Medical Officer and Chief Business Officer to advance proprietary RNA-targeted drug development programs
27 Oct 2009	Santaris Pharma's Interim Report 1 January - 30 September 2009 published
16 Sep 2009	New collaborations and breakthrough advancements in RNA-based drug development programs lead Santaris Pharma A/S to establish US operations
24 Aug 2009	Santaris Pharma A/S forms strategic alliance with Shire plc to develop RNA-based medicines for the treatment of rare genetic disorders
24 Jul 2009	Original paper: microRNAs in CNS disorders published in Neuromol Med
20 Jul 2009	Santaris Pharma presents at the World Summit of Antivirals
14 Jul 2009	Advance Access publication in Nucleic Acid Research on silencing of miRNA-155 in mice
4 Jun 2009	LNA-based HIF-1 alpha inhibitor shows early signs of clinical benefit
3 Jun 2009	Santaris Pharma Director appointed Adjunct Professor in RNA Biology
3 Jun 2009	Santaris Pharma director udnævnt til adjungeret professor i RNA biologi på Aalborg Universitet
18 May 2009	Santaris Pharma presents at Tides, Las Vegas
18 May 2009	Santaris Pharma invited speaker at microSymposium 2009, Vienna
27 Apr 2009	Santaris Pharma delivers six LNA-based RNA inhibitors to Enzon Pharmaceuticals ahead of schedule
24 Apr 2009	Santaris Pharma presents at Keystone Meeting in April
20 Apr 2009	LNA-based RNA oligonucleotides potently inhibit cancer-associated microRNAs
20 Mar 2009	Another LNA-based RNA Inhibitor Enters Clinical Trials
9 Feb 2009	LNA used to silence microRNA in murine brain
12 Jan 2009	Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
10 Nov 2008	Santaris Pharma Releases Positive Data on LNA-based Survivin Inhibitor
15 Oct 2008	New class of drug candidates developed by Santaris Pharma can potently counteract disease-associated microRNAs
15 Oct 2008	Santaris Pharmas microRNA lægemiddelkandidater hæmmer effektivt sygdomsrelaterede microRNA’er
24 Jun 2008	FierceBiotech Names Santaris Pharma as One of the “Fierce 15" Biotech Companies of 2008
23 Jun 2008	Santaris Pharma kåret som “Fierce 15" virksomhed af FierceBiotech
18 Jun 2008	Søren Tulstrup Appointed President & CEO of Santaris Pharma A/S
18 Jun 2008	Søren Tulstrup ny President & CEO i Santaris Pharma
28 May 2008	Santaris Pharma afprøver verdens første microRNA
28 May 2008	Santaris Pharma begins human clinical testing of world's first microRNA
15 May 2008	Santaris Pharma Consortium awarded 45m DKK
15 May 2008	Højteknologifonden donerer 45 millioner kroner til Santaris Pharma Konsortium som støtte til udviklingen af RNA lægemidler
26 Mar 2008	Nature publishes study by Santaris Pharma scientists and collaborators: LNA-mediated microRNA silencing in non-human primates
11 Feb 2008	Santaris Pharma to present at the Rodman & Renshaw 10th Annual healthcare Conference
11 Feb 2008	Santaris Pharma præsenterer på BioIndustry Organisations 10. årlige CEO & Investor Konference
19 Dec 2007	GlaxoSmithKline og Santaris Pharma indgår global forsknings- og udviklingsalliance. Formålet er at identificere, udvikle og markedsføre RNA antagonister som nye lægemidler mod virussygdomme
19 Dec 2007	GlaxoSmithKline and Santaris Pharma enter global R&D alliance to discover, develop and commercialise RNA antagonists as novel antivirals
18 Dec 2007	20 millioner Euro til Santaris Pharma
18 Dec 2007	Santaris Pharma raises €20 million of new equity
2 Nov 2007	Santaris Pharma’s HIF-1 alpha antagonist begins second phase 1 study
4 Jul 2007	Højteknologifonden støtter udvikling af nyt banebrydende microRNA lægemiddel
4 Jul 2007	Santaris Pharma consortium awarded €1.35m by Denmark’s Advanced Technology Foundation for development of the first microRNA medicine
19 Jun 2007	Hanne Damgaard Jensen appointed as SVP Product Development
25 May 2007	Dr Flemming Ørnskov appointed Chairman of Santaris Pharma Board
18 Apr 2007	Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
26 Jan 2007	FDA godkender Enzons ansøgning om klinisk afprøvning af Santaris Pharmas andet nye lægemiddel mod cancer
26 Jan 2007	FDA approves Enzon IND for Santaris Pharma’s Second New Cancer Drug
23 Jan 2007	Dr Walter Wenninger appointed to Santaris Pharma Board
23 Jan 2007	Walter Wenninger udnævnt til bestyrelsesmedlem i Santaris Pharma
28 Nov 2006	Santaris Pharma awarded Ernst & Young Entrepreneur of the Year 2006
6 Nov 2006	Santaris Pharma to present at Rodman & Renshaw 8th Annual Healthcare Conference - November 6th 2006
12 Oct 2006	Claus Bræstrup, CEO Lundbeck, udnævnt til Santaris Pharmas bestyrelse
12 Oct 2006	Claus Braestrup, CEO of Lundbeck, appointed to Santaris Pharma Board
27 Jul 2006	Enzon and Santaris Pharma enter into Global Collaboration to Develop Novel Cancer Therapeutics
11 May 2006	Santaris Pharma to present at Rodman & Renshaw 3rd Annual Global Health Care Conference
1 May 2006	New MicroRNA Cancer Research Collaboration
1 May 2006	Nyt MicroRNA-Forskningskonsortium
15 Mar 2006	Santaris Pharma raises EUR 40m of new equity
15 Mar 2006	Santaris Pharma rejser EUR 40 millioner i ny kapital
8 Nov 2005	FDA approves IND for SPC2996
3 Nov 2005	Santaris Pharma to present at Rodman & Renshaw 7th Annual Healthcare Conference – November 8th 2005
29 Jun 2005	Santaris Pharma sikrer mellemfinansiering på EUR 4,4 millioner (DKK 32,4 millioner) fra Selskabets hovedaktionærer og indleder Selskabets anden finansieringsrunde
29 Jun 2005	Santaris Pharma raises EUR 4.4 million
19 May 2005	Santaris Pharma initiates Phase I/II multi-centre clinical trial in Chronic Lymphocytic Leukaemia
28 Apr 2005	Santaris Pharma to present at Rodman & Renshaw Global Healthcare Conference - May 4th 2005
10 Mar 2005	LNA inhibits siRNA-mediated induction of interferon.
15 Feb 2005	LNA in siRNA Therapy: New Findings
4 Oct 2004	Lene Worsaae Dalby appointed VP Clinical Development
29 Jun 2004	Santaris Pharma raises EUR 4.4 million in interim funding from lead investors and launches second round financing
19 Jun 2004	Santaris Pharma appoints new CFO
16 Dec 2003	Santaris Pharma A/S wins decision in patent opposition case
19 May 2003	Nordic Biotechnology Merger